体重及美法仑相对剂量与POEMS综合征ASCT预处理不良反应的相关性分析

doi:10.19803/j.1672-8629.20230292

摘要/Abstract

摘要： 目的分析POEMS综合征患者接受自体外周血造血干细胞移植（ASCT）预处理中美法仑根据单位实际体重（ABW）计算的相对剂量与不良反应的关系,为临床药物剂量调整提供参考。方法回顾性分析首都医科大学宣武医院血液科收治的5例接受以大剂量美法仑为预处理方案ASCT的POEMS综合征患者的临床资料,总结治疗相关不良反应,分析与美法仑相对剂量的关系。结果 1例患者为低体重,按照ABW计算的体表面积（BSA）计算美法仑剂量进行预处理,美法仑相对剂量为5.45 mg·kg^-1,该患者移植过程中肾功能正常,出现了1级口腔黏膜炎及3级药物性肠病。中性粒细胞植入时间为+10 d,血小板植入时间为+11 d。3例患者为正常体重,按照ABW计算的BSA计算美法仑剂量进行预处理,美法仑相对剂量为4.44~5.41 mg·kg^-1,移植过程中肾功能正常,分别出现了0级（2例）、2级（1例）口腔黏膜炎,1级（1例）、2级（1例）、3级（1例）药物性肠病。中性粒细胞植入时间为+11~+13 d,血小板植入时间为+11~+13 d。1例患者为超体重,ABW为理想体重（IBW）130%,按照IBW计算的BSA计算美法仑剂量进行预处理,剂量调整后的美法仑相对剂量为4.22 mg·kg^-1,因回输干细胞中较多红细胞溶解出现肾功能不全,移植过程中出现3级口腔黏膜炎和2级药物性肠病。中性粒细胞植入时间为+11 d,血小板植入时间为+12 d。结论 POEMS综合征患者接受ASCT预处理过程中,美法仑相对剂量升高或者存在肾功能不全时,口腔黏膜炎及药物性肠病的严重程度呈增加趋势,但似乎并不影响干细胞植入。在充分预防口腔黏膜炎及药物性肠病的情况下,肥胖患者是否可以不根据体重进行美法仑剂量调整还需要大量的临床数据进一步明确。

关键词: 美法仑, 相对剂量, POEMS综合征, 自体造血干细胞移植, 口腔黏膜炎, 药品不良反应

Abstract: Objective To analyze the association of adverse reactions and the dose per actual body weight（ABW）of melphalan hydrochloride for injection in POEMS patients undergoing melphalan-based autologous stem cell transplantation (ASCT) and provide reference for clinical drug dose adjustment. Methods The clinical data of five patients with POEMS syndrome undergoing melphalan-based ASCT in the Department of Hematology of Xuanwu Hospital was analyzed retrospectively, to summary the adverse reactions and explore the association of those with relative dose of melphalan. Results One low-body-weight patient was given melphalan calculated based on BSA, with relative melphalan dose of 5.45 mg·kg^-1, had normal renal function, grade one oral mucositis(OM) and grade three drug-induced intestinal disaese(DID). Neutrophil engraftment occured on day +10, platelet on day +11. Three normal-body-weight patients were given melphalan calculated based on ABW, with relative melphalan dose of 4.44~5.41 mg·kg^-1, had normal renal function, no( two patients) and grade two (one patient) OM, grade one, two and three DID, respectively. Neutrophil engraftment occured on day +11~+13, platelets on day +11~+13. One overweight patient with ABW of 130% ideal body weight(IBW), was given melphalan calculated based on IBW, with relative melphalan dose of 4.22 mg·kg^-1, had renal insufficiency because of stem cell mixed with much lysed erythrocyte, grade three OM and grade two DID. Neutrophil engraftment occured on day +11, platelet on day +12. Conclusion In POEMS patients undergoing melphalan-based ASCT, high relative dose of melphalan and renal insufficiency may increase the grade of OM and DID, and may not affect neutrophil and platelet engraftment. Whether body weight based dose adjustment of melphalan is necessary with adequate precautions in overweight patients still need more clinical data to be verified.

Key words: melphalan, relative dose, POEMS syndrome, autologous stem cell transplantation, oral mucositis, drug adverse reactions

中图分类号:

R961

邹东梅, 方芳, 郭轶先, 倪婧, 赵弘, 胡蓉华, 孙婉玲. 体重及美法仑相对剂量与POEMS综合征ASCT预处理不良反应的相关性分析[J]. 中国药物警戒, 2023, 20(8): 911-914.

ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling. Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.

参考文献

[1] HAO Y, WANG G, ZHAO H, et al.Endocrinopathy in patients with POEMS syndrome and efficacy of chemotherapy[J]. Journal of Chinese Oncology(肿瘤学杂志), 2018, 24(10): 961-966.
[2] KIM YR.Update on the POEMS syndrome[J]. Blood Res, 2022, 57(S1): 27-31.
[3] ZHAO H, HUANG XF, GAO XM, et al.What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?[J]. Leukemia, 2019, 33(4): 1023-1029.
[4] DUAN M, ZHOU D, JIAO L, et al.Preliminary study of autologous peripheral blood stem cell transplantation in patients with POEMS syndrome[J]. Chinese Journal of Hematology(中华血液学杂志), 2010, 31(11): 744-747.
[5] D'SOUZA A, LACY M, GERTZ M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience[J]. Blood, 2012, 120(1): 56-62.
[6] LI J, ZHANG W, DUAN MH, et al.PBSC mobilization in newly diagnosed patients with POEMS syndrome: outcomes and prognostic factors[J]. Bone Marrow Transplant, 2013, 48(2): 233-237.
[7] BOGOMILOVA A, HOHN M, GUNTHER M, et al.A polyphosphoester conjugate of melphalan as antitumoral agent[J]. Eur J Pharm Sci, 2013, 50(3): 410-419.
[8] BLIJLEVENS N, SCHWENKGLENKS M, BACON P, et al.Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group[J]. J Clin Oncol, 2008, 26(9): 1519-1525.
[9] WU ZY, THOMPSON MJ, ROBERTS MS, et al.High-performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions[J]. J Chromatogr B Biomed Appl, 1995, 673(2): 267-279.
[10] NATH CE, SHAW PJ, TROTMAN J, et al.Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy[J]. Br J Clin Pharmacol, 2010, 69(5): 484-497.
[11] NATH CE, TROTMAN J, NIVISON-SMITH I, et al.Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics[J]. Bone Marrow Transplant, 2020, 55(9): 1862-1864.
[12] ALJITAWI OS, GANGULY S, ABHYANKAR SH, et al.Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation[J]. Bone Marrow Transplant, 2014, 49(8): 1042-1045.
[13] COSTA LJ, MICALLEF IN, INWARDS DJ, et al.Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma[J]. Br J Haematol, 2008, 143(2): 268-273.
[14] National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0[EB/OL]. (2017-11-27)[2023-03-18]. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
[15] NATH CE, TROTMAN J, TILEY C, et al.High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation[J]. Br J Clin Pharmacol, 2016, 82(1): 149-159.
[16] GRAZZIUTTI ML, DONG L, MICELI MH, et al.Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model[J]. Bone Marrow Transplant, 2006, 38(7): 501-506.
[17] VOKURKA S, BYSTRICKA E, SCUDLOVA J, et al.The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation[J]. Eur J Oncol Nurs, 2011, 15(5): 508-512.
[18] VOKURKA S, CHVOJKOVA I, SVOBODA T, et al.The impact of oral cryotherapy and oral and gastrointestinal mucositis after autologous stem cell transplantation[J]. Eur J Oncol Nurs, 2014, 18(2): 228-229.
[19] MALEK E, GUPTA V, CREGER R, et al.Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma[J]. Leuk Lymphoma, 2018, 59(8): 1905-1912.
[20] FAIR C, SHANLEY R, ROGOSHESKE J, et al.BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications[J]. Bone Marrow Transplant, 2017, 52(3): 491-493.
[21] VOGL DT, WANG T, PEREZ WS, et al.Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma[J]. Biol Blood Marrow Transplant, 2011, 17(12): 1765-1774.
[22] MADAN S, KUMAR SK, DISPENZIERI A, et al.High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement[J]. Blood, 2012, 119(5): 1117-1122.